Provided by Tiger Trade Technology Pte. Ltd.

Plus Therapeutics, Inc.

0.2300
-0.0129-5.31%
Post-market: 0.2270-0.0030-1.30%19:57 EDT
Volume:3.62M
Turnover:832.57K
Market Cap:39.46M
PE:-0.79
High:0.2430
Open:0.2430
Low:0.2250
Close:0.2429
52wk High:1.36
52wk Low:0.1634
Shares:171.55M
Float Shares:170.90M
Volume Ratio:1.21
T/O Rate:2.12%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2900
EPS(LYR):-1.9544
ROE:-522.50%
ROA:-83.29%
PB:9.87
PE(LYR):-0.12

Loading ...

Plus Therapeutics Prices Upsized $15 Million Public Offering

MT Newswires Live
·
Jan 15

Crude Oil Gains Over 1%; US Retail Sales Rise 0.6% In November

Benzinga
·
Jan 15

Penny Cancer Stock Plus Therapeutics Raises $15 Million At Discount, Stock Plunges

Benzinga_recent_news
·
Jan 15

Plus Therapeutics prices 39.5M units at 38c in upsized public offering

TIPRANKS
·
Jan 14

Plus Therapeutics Inc - Each Unit Sold at $0.38, Gross Proceeds Expected $15 Mln

THOMSON REUTERS
·
Jan 14

Plus Therapeutics Announces Pricing of Upsized $15 Million Public Offering

GlobeNewswire
·
Jan 14

BRIEF-Plus Therapeutics Announces Read Out Of Type B Meeting With The FDA

Reuters
·
Jan 08

Plus Therapeutics Announces Read Out of Type B Meeting With the FDA With Goal of Accelerating Approval of Reyobiq™ for Leptomeningeal Metastases

THOMSON REUTERS
·
Jan 08

Plus Therapeutics Inc - FDA Recommends Study Evaluate Endpoint With Clinical Benefit

THOMSON REUTERS
·
Jan 08

Plus Therapeutics Inc - FDA Indicates Accelerated Approval May Be Appropriate for Lm

THOMSON REUTERS
·
Jan 08

CNSide Diagnostics Expands CNSide Assay Platform to California

Reuters
·
Dec 11, 2025

Plus Therapeutics Grants Stock Options and RSUs to New CNSide Diagnostics Hires

Reuters
·
Dec 09, 2025

Plus Therapeutics completes FDA meeting on REYOBIQ development plans

TIPRANKS
·
Nov 24, 2025

Plus Therapeutics Inc : Ascendiant Capital Markets Cuts Target Price to $19 From $21

THOMSON REUTERS
·
Nov 21, 2025

Plus Therapeutics’ assay secures national coverage agreement with Humana

TIPRANKS
·
Nov 20, 2025

Plus Therapeutics CFO Andrew Sims Reports Acquisition of Common Shares

Reuters
·
Nov 05, 2025

Plus Therapeutics Q3 net loss widens

Reuters
·
Oct 31, 2025

Plus Therapeutics Q3 Net Income USD -4.423 Million

Reuters
·
Oct 31, 2025

Plus Therapeutics Q3 Operating Income USD -4.482 Million

THOMSON REUTERS
·
Oct 31, 2025

Plus Therapeutics Reports Third Quarter Financial Results and Recent Business Highlights

THOMSON REUTERS
·
Oct 31, 2025